Reimagining Medicine Q2 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Conclusions
Appendix
Innovation: Clinical trials
References
Abbreviations
2023 expected key events; all selected H1 milestones achieved
Regulatory
decisions
Cosentyx® HS
CosentyxⓇ 2ml Al
Cosentyx® IV
LeqvioⓇ Hypercholesterolemia
Submissions
Iptacopan PNH (US/EU/JP)
KisqaliⓇ HR+/HER2-BC (adj)
PluvictoⓇ mCRPC, pre-taxane (US)
Readouts
Kisqali® HR+/HER2- BC (adj)
Iptacopan IgAN Ph3
Iptacopan C3G Ph3
Ph3 starts
Iptacopan in IC-MPGN
Leqvio® CVRR primary prevention
lanalumab in immune thrombocytopenia
lanalumab in systemic lupus erythematosus
INNOVATION
H1 2023 H2 2023
Status update - as of end Q2
EU
US
EU approval in Q2
US
US approval in Q2
US
JP, China
US/EU
JP
US
US
NATALEE Ph3 FIR
APPLAUSE-IgAN Ph3
APPEAR-C3G Ph3
Filed in US and EU in Q2
EMA and FDA submissions expected Q3/Q4 2023
FDA submission expected Q4 2023
Primary endpoint met at interim analysis
Ph3
Ph3
Ph3
Ph3
HS hidradenitis suppurativa.
C3G
PNH - paroxysmal nocturnal hemoglobinuria.
complement 3 Glomerulopathy.
mCRPC metastatic castration-resistant prostate cancer.
IC-MPGN - immune complex membranoproliferative glomerulonephritis.
30 Investor Relations | Q2 2023 Results
APPARENT study
VICTORION-1P in Q1
1L (VAYHIT1) and 2L (VAYHIT2) FPFV in H1
SIRIUS-SLE 1 and 2 in Q1
FIR - first interpretable results. IgAN - immunoglobulin A nephropathy.
U NOVARTIS | Reimagining MedicineView entire presentation